Inhaled albuterol for lung disease LAM
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1/2 study tests whether breathing in albuterol can improve symptoms or lung function in people with lymphangioleiomyomatosis (LAM). It’s mainly about safety and early signs of benefit by targeting airflow problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of LAM (or LAM linked to tuberous sclerosis), based on medical testing or evidence in lungs/other organs
- You are 18 years or older
- Your breathing test shows airflow blockage (low FEV1 and a low FEV1/VC ratio)
- You are not allergic to albuterol (or its ingredients)
- You do not have moderate or large fluid around the lung (pleural effusion)
- You can stop certain breathing medicines for 24 hours before the study (and, if relevant, stop some other specific drugs for at least 7 days)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the natural history and disease process of lymphangioleiomyomatosis (LAM), a rare lung disease that mostly affects women. It may help understand how LAM progresses and how it affects daily life, and may include exercise testing and other evaluations.
This study tests the long-term safety and tolerability of the drug imatinib in women with LAM, a rare lung disease that causes cysts. It may help stabilize lung function over time.
This trial studies whether sirolimus can be used safely and works over time for LAM, a rare lung disease. You may be able to join if you already use (or cannot use) certain lung-targeting medicines called mTOR inhibitors, and if you can do regular clinic visits and breathing tests.
This trial tests a new medication called LAM-001 for people with high blood pressure in the lungs caused by lung scarring. It aims to see if it can improve symptoms and help you feel better.
This trial examines tiny particles called extracellular vesicles from your blood to see if they can help doctors understand lung problems in women with lymphangioleiomyomatosis (LAM) or tuberous sclerosis complex (TSC). It may help find new ways to track the disease without invasive tests.
This trial is a national health registry that collects medical information from women with lymphangioleiomyomatosis (LAM), a rare lung condition. It helps researchers better understand who has LAM and what their health looks like over time.
Hear when a new Lymphangioleiomyomatosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.